340 related articles for article (PubMed ID: 23806637)
1. Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.
Steinke JW; Liu L; Huyett P; Negri J; Payne SC; Borish L
J Allergy Clin Immunol; 2013 Oct; 132(4):856-65.e1-3. PubMed ID: 23806637
[TBL] [Abstract][Full Text] [Related]
2. Eosinophil production of prostaglandin D
Feng X; Ramsden MK; Negri J; Baker MG; Payne SC; Borish L; Steinke JW
J Allergy Clin Immunol; 2016 Oct; 138(4):1089-1097.e3. PubMed ID: 27423494
[TBL] [Abstract][Full Text] [Related]
3. Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease.
Steinke JW; Negri J; Liu L; Payne SC; Borish L
J Immunol; 2014 Jul; 193(1):41-7. PubMed ID: 24890720
[TBL] [Abstract][Full Text] [Related]
4. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes.
Laidlaw TM; Kidder MS; Bhattacharyya N; Xing W; Shen S; Milne GL; Castells MC; Chhay H; Boyce JA
Blood; 2012 Apr; 119(16):3790-8. PubMed ID: 22262771
[TBL] [Abstract][Full Text] [Related]
5. An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease.
Choi JH; Kim MA; Park HS
Curr Opin Allergy Clin Immunol; 2014 Feb; 14(1):1-6. PubMed ID: 24300420
[TBL] [Abstract][Full Text] [Related]
6. Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease.
Stevens WW; Ocampo CJ; Berdnikovs S; Sakashita M; Mahdavinia M; Suh L; Takabayashi T; Norton JE; Hulse KE; Conley DB; Chandra RK; Tan BK; Peters AT; Grammer LC; Kato A; Harris KE; Carter RG; Fujieda S; Kern RC; Schleimer RP
Am J Respir Crit Care Med; 2015 Sep; 192(6):682-94. PubMed ID: 26067893
[TBL] [Abstract][Full Text] [Related]
7. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.
Buchheit KM; Cahill KN; Katz HR; Murphy KC; Feng C; Lee-Sarwar K; Lai J; Bhattacharyya N; Israel E; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2016 May; 137(5):1566-1576.e5. PubMed ID: 26691435
[TBL] [Abstract][Full Text] [Related]
8. The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data.
San Nicoló M; Högerle C; Gellrich D; Eder K; Pfrogner E; Gröger M
Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):445-452. PubMed ID: 31655881
[TBL] [Abstract][Full Text] [Related]
9. Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma.
Steinke JW; Bradley D; Arango P; Crouse CD; Frierson H; Kountakis SE; Kraft M; Borish L
J Allergy Clin Immunol; 2003 Feb; 111(2):342-9. PubMed ID: 12589355
[TBL] [Abstract][Full Text] [Related]
10. Upper airways in aspirin-exacerbated respiratory disease.
Choi JH; Kim JH; Park HS
Curr Opin Allergy Clin Immunol; 2015 Feb; 15(1):21-6. PubMed ID: 25546326
[TBL] [Abstract][Full Text] [Related]
11. Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD.
Choi GS; Kim JH; Shin YS; Ye YM; Kim SH; Park HS
Clin Exp Allergy; 2013 Jul; 43(7):730-40. PubMed ID: 23786280
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome Analysis Identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in Nasal Polyp Epithelial Cells of Patients Suffering from Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (AERD).
Priyadharshini VS; Jiménez-Chobillon MA; de Graaf J; Porras Gutiérrez de Velasco R; Gratziou C; Ramírez-Jiménez F; Teran LM
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439758
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory heterogeneity in aspirin-exacerbated respiratory disease.
Scott WC; Cahill KN; Milne GL; Li P; Sheng Q; Huang LC; Dennis S; Snyder J; Bauer AM; Chandra RK; Chowdhury NI; Turner JH
J Allergy Clin Immunol; 2021 Apr; 147(4):1318-1328.e5. PubMed ID: 33189729
[TBL] [Abstract][Full Text] [Related]
14. Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis.
Bochenek G; Kuschill-Dziurda J; Szafraniec K; Plutecka H; Szczeklik A; Nizankowska-Mogilnicka E
J Allergy Clin Immunol; 2014 Jan; 133(1):98-103.e1-6. PubMed ID: 23993879
[TBL] [Abstract][Full Text] [Related]
15. Factors driving the aspirin exacerbated respiratory disease phenotype.
Steinke JW; Borish L
Am J Rhinol Allergy; 2015; 29(1):35-40. PubMed ID: 25590316
[TBL] [Abstract][Full Text] [Related]
16. Update on recent advances in the management of aspirin exacerbated respiratory disease.
Palikhe NS; Kim JH; Park HS
Yonsei Med J; 2009 Dec; 50(6):744-50. PubMed ID: 20046412
[TBL] [Abstract][Full Text] [Related]
17. Aspirin exacerbated respiratory disease: Current topics and trends.
Rodríguez-Jiménez JC; Moreno-Paz FJ; Terán LM; Guaní-Guerra E
Respir Med; 2018 Feb; 135():62-75. PubMed ID: 29414455
[TBL] [Abstract][Full Text] [Related]
18. Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease.
Steinke JW; Payne SC; Borish L
Immunol Allergy Clin North Am; 2016 Nov; 36(4):719-734. PubMed ID: 27712766
[TBL] [Abstract][Full Text] [Related]
19. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.
Mitsui C; Kajiwara K; Hayashi H; Ito J; Mita H; Ono E; Higashi N; Fukutomi Y; Sekiya K; Tsuburai T; Akiyama K; Yamamoto K; Taniguchi M
J Allergy Clin Immunol; 2016 Feb; 137(2):400-11. PubMed ID: 26194538
[TBL] [Abstract][Full Text] [Related]
20. Aspirin or other nonsteroidal inflammatory agent exacerbated asthma.
Ledford DK; Wenzel SE; Lockey RF
J Allergy Clin Immunol Pract; 2014; 2(6):653-7. PubMed ID: 25439353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
